WO2010142007A1 - Composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais - Google Patents
Composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais Download PDFInfo
- Publication number
- WO2010142007A1 WO2010142007A1 PCT/BR2009/000375 BR2009000375W WO2010142007A1 WO 2010142007 A1 WO2010142007 A1 WO 2010142007A1 BR 2009000375 W BR2009000375 W BR 2009000375W WO 2010142007 A1 WO2010142007 A1 WO 2010142007A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- prophylaxis
- humans
- animals
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A presente invenção refere-se a composições farmacêuticas que compreendem fenolatos metálicos polifuncionais que apresentam aplicações biológicas como adjuvantes antitumorais, citoprotetores, agentes antimetastáticos e agentes antimutagênicos quando associados a quimioterápicos. A presente invenção refere-se ainda ao uso fenolatos metálicos polifuncionais na preparação de medicamentos para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012514299A JP5802658B2 (ja) | 2009-06-09 | 2009-11-11 | 人および動物の腫瘍性疾患の治療、抑制あるいは予防用医薬組成物、および医薬組成物の使用 |
US13/377,194 US9381169B2 (en) | 2009-06-09 | 2009-11-11 | Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals |
EP09845661.9A EP2441452B1 (en) | 2009-06-09 | 2009-11-11 | Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0902039A BRPI0902039B8 (pt) | 2009-06-09 | 2009-06-09 | composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais |
BRPI0902039-0 | 2009-06-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010142007A1 true WO2010142007A1 (pt) | 2010-12-16 |
WO2010142007A8 WO2010142007A8 (pt) | 2012-01-26 |
Family
ID=43308327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2009/000375 WO2010142007A1 (pt) | 2009-06-09 | 2009-11-11 | Composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais |
Country Status (5)
Country | Link |
---|---|
US (1) | US9381169B2 (pt) |
EP (1) | EP2441452B1 (pt) |
JP (1) | JP5802658B2 (pt) |
BR (1) | BRPI0902039B8 (pt) |
WO (1) | WO2010142007A1 (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115414465A (zh) * | 2022-10-17 | 2022-12-02 | 苏州明人医药生物科技有限公司 | Jwa多肽在制备抗肿瘤药协同增效剂方面的应用 |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US4968733A (en) | 1988-09-01 | 1990-11-06 | Akzo N.V. | Process for producing microporous powders and membranes |
US4976859A (en) | 1988-09-01 | 1990-12-11 | Akzo N.V. | Integral asymmetric polyether-sulfone membrane, process for its production, and use for ultrafiltration and microfiltration |
US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
WO1992019195A1 (en) | 1991-04-25 | 1992-11-12 | Brown University Research Foundation | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
US5284761A (en) | 1987-11-17 | 1994-02-08 | Brown University Research Foundation | Method of encapsulating cells in a tubular extrudate |
WO1995005452A2 (en) | 1993-08-12 | 1995-02-23 | Cytotherapeutics, Inc. | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
WO1996011698A1 (en) | 1994-10-14 | 1996-04-25 | Symphony Pharmaceuticals, Inc. | Allosteric modulators of the nmda receptor |
US5618531A (en) | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
WO2001040188A1 (en) * | 1999-12-03 | 2001-06-07 | Emory University | Curcumin analogues for treating cancer |
WO2006044379A2 (en) * | 2004-10-15 | 2006-04-27 | University Of North Carolina At Chapel Hill | Novel curcumin analogues and uses thereof |
US20060258752A1 (en) * | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
US20070010488A1 (en) * | 2005-04-13 | 2007-01-11 | Khairia Youssef | Compounds for modulating cell proliferation |
WO2007075772A2 (en) * | 2005-12-20 | 2007-07-05 | President And Fellows Of Harvard College | Compounds, screens, and methods of treatment |
WO2008003155A2 (en) * | 2006-07-06 | 2008-01-10 | Uniban - Universidade Bandeirante De São Paulo - Academia Paulista Anchieta S/C Ltda | Methods to prepare penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives with antitumoral and antiparasitic properties, the compounds and their uses |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841326B2 (en) * | 2004-02-12 | 2014-09-23 | Stc.Unm | Therapeutic curcumin derivatives |
-
2009
- 2009-06-09 BR BRPI0902039A patent/BRPI0902039B8/pt active IP Right Grant
- 2009-11-11 JP JP2012514299A patent/JP5802658B2/ja not_active Expired - Fee Related
- 2009-11-11 WO PCT/BR2009/000375 patent/WO2010142007A1/pt active Application Filing
- 2009-11-11 US US13/377,194 patent/US9381169B2/en active Active
- 2009-11-11 EP EP09845661.9A patent/EP2441452B1/en not_active Not-in-force
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5284761A (en) | 1987-11-17 | 1994-02-08 | Brown University Research Foundation | Method of encapsulating cells in a tubular extrudate |
US4968733A (en) | 1988-09-01 | 1990-11-06 | Akzo N.V. | Process for producing microporous powders and membranes |
US4976859A (en) | 1988-09-01 | 1990-12-11 | Akzo N.V. | Integral asymmetric polyether-sulfone membrane, process for its production, and use for ultrafiltration and microfiltration |
US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
US5618531A (en) | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
WO1992019195A1 (en) | 1991-04-25 | 1992-11-12 | Brown University Research Foundation | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
WO1995005452A2 (en) | 1993-08-12 | 1995-02-23 | Cytotherapeutics, Inc. | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
WO1996011698A1 (en) | 1994-10-14 | 1996-04-25 | Symphony Pharmaceuticals, Inc. | Allosteric modulators of the nmda receptor |
WO2001040188A1 (en) * | 1999-12-03 | 2001-06-07 | Emory University | Curcumin analogues for treating cancer |
US20060258752A1 (en) * | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
WO2006044379A2 (en) * | 2004-10-15 | 2006-04-27 | University Of North Carolina At Chapel Hill | Novel curcumin analogues and uses thereof |
US20070010488A1 (en) * | 2005-04-13 | 2007-01-11 | Khairia Youssef | Compounds for modulating cell proliferation |
WO2007075772A2 (en) * | 2005-12-20 | 2007-07-05 | President And Fellows Of Harvard College | Compounds, screens, and methods of treatment |
WO2008003155A2 (en) * | 2006-07-06 | 2008-01-10 | Uniban - Universidade Bandeirante De São Paulo - Academia Paulista Anchieta S/C Ltda | Methods to prepare penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives with antitumoral and antiparasitic properties, the compounds and their uses |
BRPI0602640A (pt) | 2006-07-06 | 2008-02-26 | Fundacao De Amparo A Pesquisa | método de obtenção de penta-1,4-dien-3-onas de cicloexanonas substituìdas e derivados com propriedades antitumorais e antiparasitárias, processo para preparar 1,5-bis-(aril)-penta-1,4-dien-3-onas alquiladas e aciladas, processo para preparar 4-nitro-3,5-diaril-cicloexanonas substituìdas, processo para preparar 2,6-dibenzilideno-4-nitro-3,5-diaril-cicloexanonas substituìdas, processo para preparar uma mistura formada por quantidades determinadas dos compostos (1,5-bis(4-hidróxi-3-metóxi-fenil)penta-1,4-dien-3-ona) e (1,5-bis(3-metóxi-4-acetóxi-fenil)penta-1,4-dien-3-ona), compostos e seus usos, composição farmacêutica, método terapêutico para tratamento dos cánceres e composição sinérgica |
Non-Patent Citations (16)
Title |
---|
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO. |
BRANHAM, MT, MUTAT. RES., vol. 560, no. 1, 2004, pages 11 - 17 |
BRIAN K. 3 ET AL.: "Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents", BIORGANIC & MEDICINAL CHEMISTRY, vol. 12, 2004, pages 3871 - 3883, XP002417095 * |
CHEN ET AL., GEN. CANCER THERE., vol. 14, no. 12, 2007, pages 935 - 944 |
CRMV, 2008 |
FAIAO-FLORES ET AL., APPLIED CANCER RES, vol. 28, no. 2, 2008, pages 72 - 79 |
FLORES F F ET AL.: "Antiproliferative and antimetastatic activity of DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy- phenolate, in B 16F 10 melanoma", APPLIED CANCER RESEARCH, vol. 28, no. 2, 2008, pages 72 - 79, XP008150958 * |
HUANG, R., CA CANCER J. CLIN., vol. 59, 2009, pages 42 - 55 |
MARCU LG, EUR J CANCER CARE (ENGL, vol. 18, no. 2, 2009, pages 116 - 123 |
MAZU ET AL., MUTAT. RES, vol. 309, no. 2, 1994, pages 219 - 223 |
RIBEIRO ET AL.: "Environmental Mutagenesis", 2003, ULBRA PUBLISHER |
See also references of EP2441452A4 |
SHUKO, Y., HUMAN AND EXP. TOXICOL., vol. 23, no. 5, 2004, pages 245 - 250 |
SILVA, S.: "C. Evaluation of possible genotoxic effects of Gergilim", SESAMUM INDICUM L., 2003 |
SOUZA ET AL., REV. BRAS. HEMAT. HEMOTER., vol. 22, no. 2, 2000, pages 123 - 128 |
VILAR ET AL., BRAZ. J. BIOL., vol. 68, no. 1, 2008, pages 141 - 147 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115414465A (zh) * | 2022-10-17 | 2022-12-02 | 苏州明人医药生物科技有限公司 | Jwa多肽在制备抗肿瘤药协同增效剂方面的应用 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0902039A8 (pt) | 2017-10-03 |
BRPI0902039B1 (pt) | 2021-03-30 |
US9381169B2 (en) | 2016-07-05 |
BRPI0902039A2 (pt) | 2011-02-22 |
BRPI0902039B8 (pt) | 2021-05-25 |
US20120082703A1 (en) | 2012-04-05 |
WO2010142007A8 (pt) | 2012-01-26 |
EP2441452B1 (en) | 2018-12-26 |
JP5802658B2 (ja) | 2015-10-28 |
EP2441452A1 (en) | 2012-04-18 |
JP2012529439A (ja) | 2012-11-22 |
EP2441452A4 (en) | 2013-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011060049A3 (en) | Spiro-oxindole mdm2 antagonists | |
MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
MY185139A (en) | Substituted imidazopyridazines | |
WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
MX2011009847A (es) | Agentes antihelminticos y su uso. | |
UA115558C2 (uk) | Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань | |
WO2006096439A3 (en) | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases | |
UA111464C2 (uk) | Композиція, що містить моногліцериди органічних кислот c1-c7 та гліцерин, та її застосування як протибактеріального та протипліснявого засобу | |
WO2011044506A3 (en) | Sulphone compounds for use in the treatment of obesity | |
MX2010014057A (es) | Compuestos de piridina. | |
IN2012DN00624A (pt) | ||
MX348229B (es) | Derivados de 1,2,4-triazina para el tratamiento de infecciones virales. | |
MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
MX2009011869A (es) | Aislados antimicrobianos y anti-inflamatorios de extracto de regaliz. | |
WO2010121164A3 (en) | 1,4-benzodiazepinone compounds and their use in treating cancer | |
EP2438923A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY-RELATED DISORDERS MEDIATED BY AMPK ACTIVATION AND THE ACTIVE INGREDIENTS OF WHICH HAVE 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS | |
MY150931A (en) | Substituted oxazolidinones and their use | |
WO2012053009A3 (en) | Pharmaceutical compositions comprising nano size droplets of skin whitening agents | |
WO2011149301A3 (en) | A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases | |
TW200700411A (en) | Heterocyclylamide-substituted imidazoles | |
IN2012DN00763A (pt) | ||
WO2011058245A8 (fr) | Nouveaux derives de mannopyranoside ayant une activite anticancereuse | |
WO2009088992A3 (en) | Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer | |
TR200900881A2 (tr) | Tadı ve kokusu maskelenmiş stabil farmasötik bileşimler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09845661 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13377194 Country of ref document: US Ref document number: 2012514299 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009845661 Country of ref document: EP |